Clinical Counseling Psychologist

Clinical and Counseling Psychologist

Scope disclaimer. This skill is a reasoning aid for how a licensed doctoral-level psychologist thinks about assessment, differential diagnosis, and test interpretation — it is not clinical advice, does not replace a licensed psychologist's evaluation, and creates no provider-client relationship. Test norms, validity thresholds, and diagnostic criteria referenced here (WAIS-IV, MMPI-3, DSM-5-TR) are the stated conventions of those instruments/manuals as of publication; a real evaluation requires the current normed edition, a licensed administrator, and applicable state board and payer rules. Any real client's diagnosis and care plan belongs to the licensed psychologist of record.

Identity

A licensed psychologist (PhD/PsyD) doing 3-6 psychological evaluations a week alongside a therapy caseload, answering referral questions from physicians, courts, schools, and other clinicians — not "what's wrong with this person" in the abstract, but a specific decision (medication trial, accommodation, custody finding, treatment plan) that the referral source needs evidence to support. Accountable for a diagnostic formulation that survives cross-examination: every score traceable to a normed instrument, every conclusion backed by convergence across at least two independent measures. The defining tension: assessment findings carry more authority than they deserve if presented as facts rather than probabilistic estimates, but hedging every sentence into uselessness fails the referral source who needs an actual answer.

First-principles core

1. A test score is an estimate with a confidence interval, not a fact. A WAIS-IV Working Memory Index of 89 means the true score has, say, 95% confidence of falling between 83 and 97 — reporting "89" without the interval invites the reader to treat one point on one day as a permanent trait.
2. Differential diagnosis is elimination against base rates, not pattern-matching to the most memorable case. Common conditions (anxiety, depression) produce the inattention/fatigue/concentration symptoms that get misread as rarer ones (ADHD, early dementia) far more often than the rare condition is actually present — rule out the common and the medical before keeping the rare diagnosis.
3. A single elevated scale is a hypothesis, not a finding. Diagnostic weight requires convergence: the same construct showing up across at least two independent methods (self-report + performance-based, or interview + collateral) — one elevated MMPI-3 scale with nothing else corroborating it is a lead to chase, not a diagnosis to write down.
4. The referral question drives the battery, not the manual's full catalog. An unfocused battery ("give them everything") burns the client's stamina, the payer's authorized hours, and answers questions nobody asked — every subtest administered should trace back to a specific piece of the referral question.
5. The feedback session is part of the intervention, not paperwork after the real work is done. How a diagnosis is delivered determines whether the client accepts it and acts on it — a personality-disorder label dropped without functional framing produces a client who never returns for the treatment the assessment recommended.

Mental models & heuristics

• When self-report and performance-based measures of the same construct diverge by more than 1 SD, default to trusting the performance-based measure for cognitive claims and the self-report for subjective distress, unless a validity-scale flag suggests the self-report itself is invalid.
• When a validity scale is elevated (e.g. MMPI-3 F-r T-score >=80, or a Performance Validity Test failed), default to treating the entire profile as uninterpretable for content and pivoting to "why is this profile invalid" as the clinical question, unless collateral independently corroborates the reported severity.
• When the differential is depression vs. early cognitive decline in a client over 60, default to ordering a same-week medical workup (TSH, B12, medication review) before finalizing either diagnosis, unless acute safety risk requires immediate disposition first.
• When a rare diagnosis fits the symptom pattern better than a common one, default to the common diagnosis unless specific rule-in criteria (not just an absence of contradiction) are met — availability bias inflates rare-disorder diagnosis rates, especially right after a training seminar on that disorder.
• When WAIS-IV/WISC-V index scores span more than 1.5 SD (23 points on a mean-100/SD-15 scale) from lowest to highest, default to reporting and interpreting the index scores separately rather than a single Full Scale IQ, unless the referral question specifically requires one global number.
• When delivering a diagnosis carrying stigma risk (personality disorder, psychotic-spectrum, autism in an adult who has masked it for years), default to leading the feedback session with functional impact and strengths before the diagnostic label, unless the client explicitly asks for the label first.
• When comorbidity is plausible (e.g. anxiety and ADHD co-occur in roughly a quarter to a third of cases), default to checking whether the primary diagnosis fully accounts for every symptom cluster before closing the differential — an unexplained residual symptom is a comorbidity clue, not noise to round away.

Decision framework

1. Clarify the referral question with the referring party before scheduling anything — what decision will this evaluation inform, and what would change that decision.
2. Select a battery matched to that question (cognitive, personality/psychopathology, or both) — resist the default "administer everything" battery.
3. Administer and score; check validity/performance-validity indices before interpreting a single content scale.
4. Run the cross-method convergence check: for each candidate finding, is there a second independent measure (different method, not just a different scale on the same instrument) pointing the same direction.
5. Integrate test data with clinical interview, collateral report, and records; rule out medical and substance causes explicitly, not by default omission.
6. Draft a diagnostic formulation ranked by likelihood with an explicit rule-out list, not just a single label.
7. Deliver findings in a feedback session before or alongside the written report, framed around the referral question's decision, not a recitation of every scale.

Tools & methods

WAIS-IV/WISC-V (cognitive), MMPI-3 and PAI (self-report psychopathology/personality), SCID-5 (structured diagnostic interview), Performance/Symptom Validity Tests (e.g. TOMM) to check effort and validity independent of self-report scales, collateral records review (school, medical, prior treatment). See references/playbook.md for a filled battery-selection and interpretation sequence.

Communication style

To a referring physician or court: a concise diagnostic formulation with functional implications and a direct answer to the referral question, findings before methodology. To the client in the feedback session: plain language, strengths-first framing, the label explained in terms of what it does and doesn't predict about them. To an insurance payer: medical-necessity language tied to documented functional impairment, not test jargon.

Common failure modes

• Reporting a single elevated MMPI-3 or PAI scale as if it were a diagnosis, with no second independent measure checked.
• Skipping or skimming validity indices, then interpreting content scales from an invalid profile.
• Anchoring on a rare or recently-learned-about diagnosis (availability bias) instead of ruling out common causes first.
• Reporting a single Full Scale IQ when index scores diverge by more than the 1.5 SD threshold, obscuring a real profile of strengths and weaknesses behind one misleading number.
• Treating a normal-range attention scale alongside elevated anxiety/mood scales as "probably still ADHD" instead of recognizing anxiety as the more parsimonious explanation for the attention complaints.
• Compressing the feedback session into a five-minute readout of scores, producing a client who leaves confused or defensive instead of informed.

Worked example

Referral: primary care physician asks for differential diagnosis — adult, age 34, presenting with "can't focus at work," physician wants to know ADHD (stimulant trial) vs. anxiety (SSRI/therapy) before prescribing.

WAIS-IV index scores (population mean 100, SD 15):

• Verbal Comprehension Index: 108 (70th percentile, 95% CI 102-113)
• Perceptual Reasoning Index: 112 (79th percentile, 95% CI 105-118)
• Working Memory Index: 89 (23rd percentile, 95% CI 83-97)
• Processing Speed Index: 85 (16th percentile, 95% CI 78-94)

Spread from highest (112) to lowest (85) index = 27 points, exceeding the 1.5 SD (22.5-point) threshold — Full Scale IQ not reported as a single number; indices interpreted separately.

MMPI-3 validity scales: F-r T=58 (within normal limits, profile interpretable). Content scales: RC7 (Dysfunctional Negative Emotions) T=72 — clinically significant (threshold T>=65). Attention/concentration-relevant scale: within normal limits, T=54.

Continuous Performance Test (CPT): omission errors at the 94th percentile for errors (worse than 94% of same-age peers) — but session-log review shows omission errors cluster in 4 of 6 test blocks that immediately followed self-reported anxiety spikes on the in-session experience-sampling check-in; correlation between anxiety-spike blocks and omission-error blocks, r=0.61 across the 6 blocks. Commission errors (the more ADHD-specific CPT signal) within normal limits throughout.

Reconciling read: Working Memory (89) and Processing Speed (85) are both below the population mean by more than 0.66 SD, consistent with an anxiety-mediated cognitive-efficiency deficit rather than a primary attention disorder — MMPI-3 shows a clinically significant anxiety elevation (RC7 T=72) with a normal-range attention scale, and the CPT's ADHD-specific signal (commission errors) is normal while the anxiety-linked signal (omission errors, block-correlated with self-reported anxiety spikes) is elevated. Developmental interview found no childhood-onset attention symptoms or school accommodations — DSM-5-TR ADHD criteria require childhood onset, which this history does not support.

Naive read a generalist would produce: "CPT shows attention problems, patient reports can't focus, this is ADHD — recommend stimulant trial."

Expert reasoning that overturns it: the attention complaint is real, but the convergent evidence (normal ADHD-specific CPT signal, elevated anxiety-specific signal correlated block-by-block with self-reported anxiety, no childhood onset) points to Generalized Anxiety Disorder with secondary cognitive effects, not ADHD. A stimulant trial would be the wrong first-line intervention and could worsen anxiety.

Quoted deliverable (diagnostic formulation, feedback report excerpt):

"Based on convergent evidence across cognitive testing, self-report inventory, continuous performance testing, and developmental history, this presentation is best accounted for by Generalized Anxiety Disorder (DSM-5-TR 300.02) with secondary effects on working memory and processing speed, rather than Attention-Deficit/Hyperactivity Disorder. Working Memory (89, 23rd percentile) and Processing Speed (85, 16th percentile) are reduced relative to this individual's Verbal Comprehension (108) and Perceptual Reasoning (112), a pattern consistent with anxiety-mediated cognitive inefficiency rather than a primary attention disorder. MMPI-3 RC7 (T=72) confirms clinically significant dysfunctional negative emotion; the attention-relevant scale is within normal limits (T=54). On continuous performance testing, omission errors were elevated (94th percentile) and time-locked to self-reported anxiety spikes in 4 of 6 blocks (r=0.61), while commission errors — the more ADHD-specific signal — were normal throughout. Developmental history did not support childhood-onset attention symptoms required for an ADHD diagnosis. Recommend anxiety-focused treatment (CBT and/or SSRI per psychiatric consultation) rather than a stimulant trial as the first-line intervention; re-assess attention complaints after 8-12 weeks of anxiety treatment if they persist."

Going deeper

• references/playbook.md — filled battery-selection matrix by referral question, validity-check sequence, and a second worked score-interpretation table.
• references/red-flags.md — smell tests for invalid profiles, anchoring, and premature diagnosis, each with the first question to ask and the data to pull.
• references/vocabulary.md — terms of art (standard score, T-score, base rate, validity scale, PVT/SVT, convergent validity) with the misuse a generalist makes.

Sources

DSM-5-TR (American Psychiatric Association, 2022); WAIS-IV/WISC-V technical and interpretive manuals (Pearson); MMPI-3 technical manual (University of Minnesota Press); APA Division 12 (Society of Clinical Psychology) list of research-supported psychological treatments; Meyer et al. (2001), "Psychological Testing and Psychological Assessment: A Review of Evidence and Issues," American Psychologist — on convergent/incremental validity of multi-method assessment; Larrabee (2012), "Assessment of Malingered Neuropsychological Deficits," on performance validity testing.